Eldrin F. Lewis, MD, MPH; Ajay K. Singh, MBBS, FRCP, MBA
This activity is jointly provided by Global Education Group and Integritas Communications.
This educational activity is supported by an educational grant from GlaxoSmithKline.
The educational design of this activity addresses the needs of nephrologists, cardiologists, hematologists, endocrinologists, internal medicine physicians, and other clinicians involved in the management of patients with anemia associated with chronic kidney disease (CKD).
Faculty Dr. Ajay Singh and Dr. Eldrin Lewis present the current challenges in patient-reported outcomes research in anemia in CKD. They discuss potential current bias that results in undertreatment of anemia and under-selection of Black patients for kidney transplant. By examining the results of the TREAT (ie, injectable darbepoetin alfa, an erythropoiesis-stimulating agent [ESA]) and the ASCEND-NHQ studies (ie, oral HIF-PH inhibitor, daprodustat), they propose that HIF-PH inhibitors may address disparities in care and health-related quality of life, and offer an additional treatment option for those hyporesponsive to traditional ESAs.
After completing this activity, the participant should be better able to:
- Discuss the mechanisms of action and clinical trial data for emerging treatment options, such as hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, in the treatment of anemia associated with CKD
- Tailor management regimens for anemia associated with CKD to reflect disease presentation, treatment responses, efficacy and safety of available therapies, and efforts to address disparities in health care and patient outcomes
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor of Medicine
Chief, Division of Cardiovascular Medicine
Ajay K. Singh, MBBS, FRCP, MBA
Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) Program
Harvard Medical School
Physician, Renal Division
Brigham and Women’s Hospital/ Dana Farber Cancer Institute
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hour(s) of pharmacology).
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must pass the posttest with 100% and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Eldrin F. Lewis, MD, MPH: Consulting Fee: Akebia Therapeutics Inc., Merck & Co., Novartis AG; Contracted Research: Merck & Co., Novartis AG
Ajay K. Singh, MBBS, FRCP, MBA: Consulting Fee: GlaxoSmithKline plc, Bayer AG, Zydus Lifesciences Limited, Nephrology Times
The following planners and managers have no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Lauren Sinclair, Stacey JP Ullman, MHS, Celeste Collazo, MD, Jim Kappler, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications Group do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.25
credit type CME/CE
New Avenues to Improve Patient Outcomes